Johnson & Johnson (JNJ) is listed on NYSE in the Healthcare sector Β· Drug Manufacturers - General industry. The current price is 278.10, up 1.05% from the previous close. Market cap is approximately $669.5B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
Johnson & Johnson trades at a premium P/E of 32.23x, with a lot of growth priced in. A single quarter that misses consensus can compress the multiple sharply.
Johnson & Johnson's 25.74% ROE places it in the elite band. Companies that sustain ROE above 15% for years usually have a structural moat (brand, network effects, cost advantage).
D/E of 57.71 indicates high leverage. Watch interest coverage and free cash flow closely, especially across rate cycles.
JNJ's 6.60% revenue growth is modest. In this band, buybacks and dividends often drive most of the EPS and total return.
Johnson & Johnson's 1.98% yield is standard. If the company is also buying back stock, evaluate on total shareholder return (dividends + buybacks) rather than yield alone.
Demographic-driven structural demand growth is a long-running tailwind for healthcare.
Johnson & Johnson is near its 52-week high (281.07), in the top 3% of the range. Prices close to new highs invite two readings β little overhead supply, or stretched expectations β and volume is the usual tiebreaker.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The stock moved within a 2.03% high-to-low band on the day, closing 1.05%. That falls within a typical intraday range.
Johnson & Johnson (JNJ) is listed on NYSE, with recent volume of 2,006,891 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.